<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite the success of standard treatments in <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) and non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), patients are often unable to tolerate aggressive regimens, and they require effective alternatives </plain></SENT>
<SENT sid="1" pm="."><plain>Bendamustine is a bifunctional alkylator with unique properties that significantly distinguish it from other agents in its class </plain></SENT>
<SENT sid="2" pm="."><plain>In untreated CLL, bendamustine has demonstrated rates of response and progression-free survival (PFS) that are superior to those with <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>, with an acceptable toxicity profile </plain></SENT>
<SENT sid="3" pm="."><plain>In the relapsed setting, combination treatment with bendamustine-rituximab (BR) has demonstrated promising activity in high-risk patients such as those refractory to fludarabine or <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In untreated patients with indolent NHL and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, BR has demonstrated a PFS significantly longer than that achieved with R-CHOP (rituximab-<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>-<z:chebi fb="0" ids="28748">doxorubicin</z:chebi>-<z:chebi fb="0" ids="28445">vincristine</z:chebi>-<z:chebi fb="0" ids="8382">prednisone</z:chebi>), with significantly reduced toxicity </plain></SENT>
<SENT sid="5" pm="."><plain>In the relapsed setting, br has demonstrated rates of response and PFS superior to those with fludarabine-rituximab, with comparable toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>In the United States and Europe, bendamustine has been approved for the treatment of CLL and indolent NHL; its approval in Canada is pending and eagerly awaited </plain></SENT>
<SENT sid="7" pm="."><plain>Once available, bendamustine will benefit many Canadian patients with NHL and CLL </plain></SENT>
</text></document>